New Castle County Chamber of Commerce named Liz Scott, co-executive director of Alex’s Lemonade Stand Foundation and mother to founder Alexandra “Alex” Scott, as the keynote speaker for its 26th Annual Entrepreneurial & Business Women’s Expo.
Registration is open for the expo, scheduled for 9 a.m. to 6 p.m. Nov. 17 at the Chase Center on the Riverfront. This event is designed to motivate and inspire all businesswomen by providing exciting networking opportunities, as well as educational workshops and programs.
Alex’s Lemonade Stand is a childhood cancer foundation dedicated to raising funds for research into new treatments and cures for all children battling cancer. Liz and her husband Jay happily served as helpers to their daughter, after she decided to hold a lemonade stand to help other children with cancer. The grassroots effort grew into a national movement following Alex’s untimely death at the age of 8 in 2004.
Scott will speak about the story of her daughter as the motivation for Alex’s Lemonade Stand Foundation, how to make a difference, and more.
NCCCC President Mark Kleinschmidt encourages registrants to kindly add a $5 donation to Alex’s Lemonade Stand Foundation at the time of registration. For registration details and sponsorship opportunities visit www.ncccc.com.
Zimmer Biomet acquires Claymont-based CD Diagnostics
Zimmer Biomet has acquired CD Diagnostics, based in Claymont. Zimmer Bionet and CD Diagnostics initially partnered in 2012 to co-develop and market diagnostics in the field of musculoskeletal health care.
As part of the original agreement, Zimmer Biomet successfully marketed the Synovasure Periprosthetic Joint Infection test, the first and only test specifically designed and validated
for the disease. CD moved operations from Pennsylvania to Delaware a few years ago.
“I formed CD Diagnostics to solve the frustrating problem of diagnosing PJI and the complications associated with misdiagnosis, including the pain and incremental costs-of-care following joint replacement surgery. As a leader and visionary in musculoskeletal health care, Zimmer Biomet is the ideal partner to leverage our expertise in biomarker detection and immunoassay development, and to elevate the value of diagnostics in the treatment of musculoskeletal conditions,” said Dr. Carl Deirmengian, scientific founder of CD Diagnostics.
Richard Birkmeyer, CEO of CD, was instrumental in moving the company to Delaware. He formerly headed Strategic Diagnostics in Newark.
CD Diagnostics is focused on analyzing biomarker profiles for various clinical conditions in synovial fluid (a viscous fluid that reduces friction between articular cartilage), and creating diagnostic assays that help physicians make informed decisions that optimize patient care. More than 40,000 samples have been evaluated at CD Diagnostics’ laboratories resulting in more than 15 peer-reviewed publications.
